For the fourth quarter ended , Par reported total prescription medicines revenues of $161.3 million and a loss from continuing operations of $30.5 million, or $0.91 per share. By comparison, and in addition to the fourth quarter 2007 events cited above, reported GAAP income from continuing operations for the full year aldara 2007 included a $20.0 million gain on the sale to Optimer of marketing rights to the investigational drug list of antibiotics produced by sandoz Difimicin (Par 101), a $4.5 million investment gain antibiotics
on the sale of shares of Optimer com stock, and aciclovir net settlement gains of $0.6 million.
Par's fish antibiotic penicillin alternative reported, or GAAP, loss from continuing operations for the year ended , included the write-off of an intangible asset and certain inventories related to the trimming of antibiotics its generic product cymbalta reviews anxiety portfolio of $5.5 tetracycline
million, a charge related to a government pricing contingency of $4.8 million, a $7.8 million net impairment charge related to various investments, valacyclovir $7.5 million in development milestone payments to MonoSol Rx and Alfacell, and $9.0 million of gains from the sale of non-core xyzal after expiration ANDAs and other product rights. Par Pharmaceutical Reports Fourth Quarter and Full genital herpes Year 2008 Results
WOODCLIFF LAKE, N.J., / - / -- Par Pharmaceutical Companies, Inc. Adjusting for these items and the fourth quarter special items, income from continuing operations for the full year ended would have been $1.8 million, or $0.05 per diluted share. These benefits were tempered by $19.2 million of costs related to business development activities in support of Strativa Pharmaceuticals, ospamox 500mg antibiotic what is it for i Par's branded division, a $6.0 million loss on prescription drugs an investment, $1.6 million of severance costs. Adjusting for these items, income from continuing operations for the full year ended would have been $55.1 million, or.
By comparison, fourth quarter 2007 results included a pre-tax gain zithromax of $3.1 million from Par's sale online prescriptions viagra of its remaining investment in Optimer Pharmaceutical, Inc. Fourth quarter 2008 reported, or GAAP, loss from continuing operations also included the write-off acyclovir of a restructuring charge of $15.4 synthroid with herbal supplements tetracyclin
supplement million and other related costs of $3.8 million, $49.2 million in charges due to an unfavorable court decision and related legal fees, $5.3 million gain on non-core tetracyclin ANDA sales and the sale of other product rights, $4.9 million azithromycin 250 mg help sinus infections sinu infection impairment charge related to various investments, and a $7.9 million gain related to keven debt extinguishment. This is compared with reported revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share, sleeping pills in market pill for the same prescription medication period in 2007. Adjusting for these items, income from continuing operations for the fourth quarter of 2007 would have been $6.5 million, or $0.19 per diluted share. For the year ended , Par reported total revenues of $578.1 million and a loss from continuing operations of $45.9 million, or $1.38 per share.
Com stock and $4.6 million of additional share-based compensation expense related to Par's employee stock option tender offer. Adjusting for is it ok to get a tetanus shot while on antibiotics i tetanu these items and other special items, income from continuing operations for the fourth quarter 2008 would have been $7.1 million, or $0.21 per diluted share. This is compared with reported revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share, for 2007. PRX) today reported fourth quarter and full year 2008 results ended.
There are no comments on this page. [Add comment]